MX388038B - Uso de molindona para el tratamiento de agresión. - Google Patents

Uso de molindona para el tratamiento de agresión.

Info

Publication number
MX388038B
MX388038B MX2019001413A MX2019001413A MX388038B MX 388038 B MX388038 B MX 388038B MX 2019001413 A MX2019001413 A MX 2019001413A MX 2019001413 A MX2019001413 A MX 2019001413A MX 388038 B MX388038 B MX 388038B
Authority
MX
Mexico
Prior art keywords
aggression
treatment
molindone
impulsivity
irritability
Prior art date
Application number
MX2019001413A
Other languages
English (en)
Other versions
MX2019001413A (es
Inventor
Christopher D Breder
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of MX2019001413A publication Critical patent/MX2019001413A/es
Publication of MX388038B publication Critical patent/MX388038B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a un método de tratamiento de agresión y síndromes de comportamiento similares, tales como impulsividad e irritabilidad, mediante un agente farmacéutico que exhibe actividad antagonística de D2 y D5 combinada.
MX2019001413A 2008-12-19 2009-12-18 Uso de molindona para el tratamiento de agresión. MX388038B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19373508P 2008-12-19 2008-12-19
PCT/US2009/068707 WO2010080603A2 (en) 2008-12-19 2009-12-18 Method of treatment of aggression

Publications (2)

Publication Number Publication Date
MX2019001413A MX2019001413A (es) 2019-08-12
MX388038B true MX388038B (es) 2025-03-19

Family

ID=42312104

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2011006463A MX2011006463A (es) 2008-12-19 2009-12-18 Metodo de tratamiento de agresion.
MX2014010480A MX362853B (es) 2008-12-19 2009-12-18 Uso de molindona para el tratamiento de agresión.
MX2019001413A MX388038B (es) 2008-12-19 2009-12-18 Uso de molindona para el tratamiento de agresión.
MX2021013281A MX2021013281A (es) 2008-12-19 2011-06-16 Uso de molindona para el tratamiento de agresion.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2011006463A MX2011006463A (es) 2008-12-19 2009-12-18 Metodo de tratamiento de agresion.
MX2014010480A MX362853B (es) 2008-12-19 2009-12-18 Uso de molindona para el tratamiento de agresión.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013281A MX2021013281A (es) 2008-12-19 2011-06-16 Uso de molindona para el tratamiento de agresion.

Country Status (7)

Country Link
US (5) US20100173907A1 (es)
EP (1) EP2367544A4 (es)
JP (3) JP5783908B2 (es)
AU (3) AU2009335709A1 (es)
CA (2) CA3014688A1 (es)
MX (4) MX2011006463A (es)
WO (1) WO2010080603A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10310415A1 (de) * 2003-03-11 2004-09-30 Bayer Ag Verfahren zur An- und Abmeldung von Produkten und deren gefärbten Einstellungen
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
US8748472B2 (en) 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
CA2888725A1 (en) * 2012-11-13 2014-05-22 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
EP3449402A1 (en) * 2016-04-29 2019-03-06 Supernus Pharmaceuticals, Inc. Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148896A (en) 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US6489319B2 (en) 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
ATE391495T1 (de) 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
FR2814463B1 (fr) 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US6613763B2 (en) 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
PL370793A1 (en) 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
DE10149108A1 (de) 2001-10-05 2003-04-30 Degussa Bioactives Deutschland Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS)
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2003296672A1 (en) 2002-12-13 2004-07-09 Cilag Ag Controlled release preparations comprising tramadol and topiramate
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
AU2005223637A1 (en) * 2004-03-18 2005-09-29 University Of Virginia Patent Foundation Method, apparatus, and computer program product for stochastic psycho-physiological assessment of attentional impairments
MXPA06013762A (es) * 2004-05-27 2007-02-08 Warner Lambert Co Combinacion de atomoxetina y un agonista del receptor 5t1a para el tratamiento de trastorno de hiperactividad con deficit de atencion y otros trastornos.
AR049512A1 (es) 2004-06-14 2006-08-09 Janssen Pharmaceutica Nv Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
ES2953390T3 (es) 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8637080B2 (en) * 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
US8748472B2 (en) 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
SE536078C2 (sv) 2010-10-09 2013-04-30 Core Link Ab Anordning för bearbetning av hylsor
CA2888725A1 (en) 2012-11-13 2014-05-22 Supernus Pharmaceuticals, Inc. Method of treatment of aggression

Also Published As

Publication number Publication date
MX362853B (es) 2019-02-20
JP2017149757A (ja) 2017-08-31
AU2015221441A1 (en) 2015-09-17
JP2015164942A (ja) 2015-09-17
CA3014688A1 (en) 2010-07-15
JP5783908B2 (ja) 2015-09-24
CA2746509A1 (en) 2010-07-15
JP2012512897A (ja) 2012-06-07
MX2011006463A (es) 2011-07-20
JP6316480B2 (ja) 2018-04-25
AU2009335709A1 (en) 2011-07-14
US20100173907A1 (en) 2010-07-08
AU2017204229B2 (en) 2018-05-31
US20180325912A1 (en) 2018-11-15
MX2021013281A (es) 2022-06-02
AU2015221441B2 (en) 2017-06-15
US11638708B2 (en) 2023-05-02
US10058556B2 (en) 2018-08-28
EP2367544A4 (en) 2016-06-08
MX2019001413A (es) 2019-08-12
WO2010080603A2 (en) 2010-07-15
CA2746509C (en) 2018-11-20
AU2015221441C1 (en) 2017-09-21
JP6133354B2 (ja) 2017-05-24
US10201547B2 (en) 2019-02-12
AU2017204229A1 (en) 2017-07-13
EP2367544A2 (en) 2011-09-28
US20200022986A1 (en) 2020-01-23
US20180055853A1 (en) 2018-03-01
US20140187552A1 (en) 2014-07-03
WO2010080603A9 (en) 2010-11-18
US9801887B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
CY1122358T1 (el) C-τελικοι hsp90 αναστολεις
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
ECSP11011183A (es) Compuestos orgánicos
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
MY177564A (en) Anti-nr10 antibody and use thereof
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
TW200739980A (en) Method for preparing doped organic semiconductor materials and formulation utilized therein
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
MX2013001845A (es) Polipetidos que enlazan miostatina, composiciones y metodos.
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201270590A1 (ru) Ингибиторы акт
CO6310993A2 (es) Moleculas utiles para el control de insectos
MX347323B (es) Formulaciones de agente de curtido particulado sólido.
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
BR112013012571A2 (pt) composições fungicidas e métodos
EP2646447A4 (en) CHINOLINE- [3,2,1-KL-] PHENOXAZINE COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT THEREWITH
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.